Literature DB >> 18059480

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML.

H Hasle, J Abrahamsson, M Arola, A Karow, A O'Marcaigh, D Reinhardt, D K H Webb, E van Wering, B Zeller, C M Zwaan, P Vyas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18059480     DOI： 10.1038/sj.leu.2405060

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

Review 1.  Acute leukemia in children with Down syndrome.

Authors:  Ana C Xavier; Jeffrey W Taub
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

Review 2.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

3.  Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.

Authors:  Anindita Roy; Gillian Cowan; Adam J Mead; Sarah Filippi; Georg Bohn; Aristeidis Chaidos; Oliver Tunstall; Jerry K Y Chan; Mahesh Choolani; Phillip Bennett; Sailesh Kumar; Deborah Atkinson; Josephine Wyatt-Ashmead; Ming Hu; Michael P H Stumpf; Katerina Goudevenou; David O'Connor; Stella T Chou; Mitchell J Weiss; Anastasios Karadimitris; Sten Eirik Jacobsen; Paresh Vyas; Irene Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

4.  Transient abnormal myelopoiesis/acute megakaryoblastic leukemia diagnosed in the placenta of a stillborn Down syndrome fetus with targeted next-generation sequencing.

Authors:  B Federmann; A Fasan; K O Kagan; S Haen; F Fend
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

Review 5.  Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Authors:  J Timothy Caldwell; Yubin Ge; Jeffrey W Taub
Journal:  Expert Rev Hematol       Date:  2014-09-18       Impact factor: 2.929

6.  Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.

Authors:  Kazuko Kudo; Asahito Hama; Seiji Kojima; Ruriko Ishii; Akira Morimoto; Fumio Bessho; Shosuke Sunami; Naoyuki Kobayashi; Akitoshi Kinoshita; Yuri Okimoto; Akio Tawa; Ichiro Tsukimoto
Journal:  Int J Hematol       Date:  2010-03-18       Impact factor: 2.490

Review 7.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

Review 8.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Authors:  Sébastien Malinge; Shai Izraeli; John D Crispino
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

9.  Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.

Authors:  Marjolein Blink; Martin Zimmermann; Christine von Neuhoff; Dirk Reinhardt; Valerie de Haas; Henrik Hasle; Maureen M O'Brien; Batia Stark; Julie Tandonnet; Andrea Pession; Katerina Tousovska; Daniel K L Cheuk; Kazuko Kudo; Takashi Taga; Jeffrey E Rubnitz; Iren Haltrich; Walentyna Balwierz; Rob Pieters; Erik Forestier; Bertil Johansson; Marry M van den Heuvel-Eibrink; C Michel Zwaan
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

Review 10.  Down syndrome and leukemia: insights into leukemogenesis and translational targets.

Authors:  Marion K Mateos; Draga Barbaric; Sally-Anne Byatt; Rosemary Sutton; Glenn M Marshall
Journal:  Transl Pediatr       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.